Cipia Vision 2025: The Remaining Business Is Tiny, and the Bridge to Tomer Is Now the Whole Story

Getting To Know The Company

Cipia at the end of 2025 is no longer really an automotive computer-vision company in the way most investors used to think about it. In July 2025 it sold most of the assets and liabilities tied to its core business to Red Bend, a Harman group subsidiary, and kept only the aftermarket activity of selling CIPIA FS-10 units to fleet customers. The company explicitly states that after the sale it no longer holds material intellectual property rights for its remaining activity. That has to be the starting point for reading the report. Anyone still reading this as another year in a tech-commercialization story is reading the wrong company.

What is still working today? There is still a cash balance of $3.1 million, no meaningful bank debt at the listed-company level, and some limited sales to existing customers. What is not working? The remaining activity is too small to support a public company, it depends sharply on both a dominant customer and a dominant supplier, and in March 2026 Royaltek added another operational hit by warning of a significant component delay. From here, this is no longer a scale-up story. It is a bridge story. Either the company closes the Tomer deal and becomes the public shell for a food-distribution business, or it is left with a business tail that is too thin and with a going-concern warning still hanging over it.

The superficial reading would stop at the headline that total loss narrowed from $8.0 million in 2024 to $2.9 million in 2025. That is the wrong read. The continuing business did not heal. Total loss from continuing operations actually worsened slightly to $3.283 million from $3.174 million, and operating cash flow remained negative at $3.978 million. What improved the reported total was the swing in discontinued operations from a $4.842 million loss to a $391 thousand profit, mainly because of a $2.537 million gain on the asset sale.

So the right way to think about Cipia now is as a public shell with three very different economic layers: a tiny and fragile continuing business, a balance sheet cleaned up through the sale of the core business, and a Tomer transaction that could replace the operating engine, the control structure, the company name, and the risk profile. It is also a stock with a real actionability constraint. Market value is only about NIS 29 million, and the latest daily trading turnover was about NIS 64 thousand. Anyone trying to read a pure tech upside story here without passing through liquidity, dilution, and business-model replacement is missing the point.

Events And Triggers

Selling the core business changed the definition of the company

The major event of 2025 was not another customer win or another pilot. It was the sale of the core business itself. In April 2025 the board adopted an efficiency plan that included cutting roughly 50% of headcount, reducing the executive team, and having directors waive their fees through year-end. In June the asset sale agreement was signed, and on July 29 the transaction closed. Cash consideration was about $3.9 million after adjustments, and the technology, intellectual property, part of the contracts, and part of the liabilities moved to the buyer.

The meaning is deeper than the balance-sheet line item. The sale did not just shrink the company. It changed what the investor should be measuring. Until July 2025 it still made sense to ask whether the technology could scale into stable revenue. After July 2025 the real question became what is left after the core is sold, and whether what remains is enough to carry the bridge into the next transaction.

The aftermarket activity remains, but as a tail rather than a standalone business

Cipia kept the aftermarket activity, meaning sales of CIPIA FS-10 units to existing fleet customers. But here too, it is important to distinguish between the formal existence of an activity and a business that can support a real thesis. Under the agreements with the buyer, the company was allowed to sell up to 9,000 units, and the December 2025 amendment extended that window through June 30, 2026. Beyond that, additional unit sales would require an $11 per unit royalty and additional terms to be agreed with the buyer.

That does not look like a clean growth engine. It looks like a right to manage inventory and a residual activity inside a limited time window. Once the company adds that it no longer holds material intellectual property for the remaining activity, the picture becomes much clearer. The aftermarket is a tail built to serve an interim period, not a clean base for rebuilding.

The Tomer transaction is not an add-on, it is an identity swap

On January 20, 2026 the binding agreement to acquire Tomer Import and Marketing of Food Products was signed, and it was amended in February and March 2026. After the second amendment, Doron Kimlov is expected to receive shares representing 70.99% of the company immediately after issuance, and the promoter is expected to receive 4%. The minimum cash condition was also raised from NIS 8.0 million to NIS 8.375 million.

That dilution is not a technical footnote. It is the center of the event. If the deal closes, Cipia is not merely adding a business. It is effectively replacing its operating core. The company is expected to change its name, execute a 1:10 share consolidation, and become the listed vehicle through which Tomer trades. For existing shareholders, the transaction may solve the problem of scale, but it does so at the cost of becoming a minority in a very different business.

The immediate operating trigger is negative, not positive

If there is a short-term trigger in the remaining activity, it came from the negative side. On March 9, 2026 Royaltek, Cipia’s material supplier for the CIPIA FS-10 product, warned that supply times would stretch from up to two months to at least about three months because of component shortages. In the company’s own wording, that timeframe does not allow it to meet customer demand, meaning it can sell only from existing inventory, and that inventory was described as immaterial.

That matters because it means the bridge until Tomer is not resting on a tech business that still knows how to supply. It is resting on residual inventory and on the hope that the Tomer deal closes before the remaining business runs out of road.

Efficiency, Profitability And Competition

The operating story of the continuing business in 2025 is a paradox. On one side, management cut expenses almost everywhere it could. On the other side, the business left behind is so small that even after the cuts it can no longer generate a positive gross profit.

Continuing revenue fell to $1.456 million from $1.812 million in 2024. That alone looks like an expected consequence of shrinking the business. But cost of revenue actually rose to $1.867 million from $1.460 million, turning a $352 thousand gross profit in 2024 into a $411 thousand gross loss in 2025.

The sharpest reason for that deterioration is not ordinary pricing pressure. It is residual commitments from the old business. The company says explicitly that the main driver of higher cost of revenue was the recognition of a $725 thousand expense tied to a commitment to purchase components for fleet-monitoring units, and the cost note also shows a $117 thousand inventory write-down. This is the operating core of the story. The remaining business is not just small. It is also still carrying legacy supply-chain obligations from a business that has already been sold.

On the cost side, the cuts were real:

R&D fell from $491 thousand to $81 thousand. Sales and marketing fell from $1.355 million to $650 thousand. G&A fell from $2.103 million to $1.968 million. In other words, the company did almost everything it could to adjust the cost base to the new reality. And still, the continuing operating loss was $3.110 million. The reason is simple. When revenue is only $1.456 million, even a reduced public-company cost base is still too large.

The headcount data shows the same story in a harsher way:

The company ended 2024 with 62 employees. It ended 2025 with 5. There were zero R&D employees left, one person in sales, product, and operations, and four in G&A. That is not the headcount of a public tech company trying to rebuild a commercialization engine. It looks much more like a shell preserving what remains while searching for a transaction.

Competition is no longer the main problem

The company still lists competitors such as Smart Eye, Seeing Machines, LightMetrics, Streamax, and MiTac, and says it is difficult to assess market share. But at the level of 2025, this is no longer the central analytical question. The main issue is not whether the product is good enough against a rival. It is whether the company even has the commercial and operational ability to stay in the game.

The report itself hints at this. All continuing revenue is recognized at a point in time, the company sells to existing customers only, and the text says customers of the CIPIA FS-10 are examining alternatives in light of the reduction in the company’s activity. So even without a rival taking business away aggressively, the company’s own shrinkage is already pushing customers to look elsewhere.

Concentration has become extreme

One of the sharpest points in the filing sits in the customer page. In the narrative text, the company names INTCOMEX and Tracking Hardware as major customers. But the quantitative table reveals something even harsher. INTCOMEX alone represented 87% of 2025 revenue, and another unnamed customer represented 10%. That means 97% of revenue came from just two customers.

This is no longer ordinary concentration for a small growth company. It is the concentration of a residual activity. Once it sits in parallel with a single material supplier, Royaltek, the economic structure becomes highly fragile. A key customer can reduce orders, a key supplier can delay delivery, and the company has very little buffer in between.

Cash Flow, Debt And Capital Structure

Here it is important to state the cash framework explicitly. In Cipia’s case, the relevant lens is all-in cash flexibility, not normalized cash generation. The reason is simple. This is no longer about how much cash the existing business could produce in a stable state. It is about how much room the company has left after selling the core business, burning cash in the residual activity, repaying debt, and trying to reach the Tomer closing line.

Operating cash flow in 2025 was negative $3.978 million. The continuing activity is still burning cash. What offset that was $5.152 million of investing inflow, mainly from $3.902 million of proceeds from selling the business, $1.0 million of released restricted cash, and $238 thousand of released restricted deposits. At the same time, financing outflow was $3.497 million, driven mainly by $2.999 million of bank-loan repayments, $200 thousand of lease principal payments, and $240 thousand of interest.

The right reading of that bridge is that the company bought time. It did not build a new engine. The sale proceeds covered both the cash burn and the cleanup of bank debt. The result is a cleaner balance sheet, but also a much smaller business.

That is why the combination of the following numbers matters so much:

The debt cleanup is positive, but it is also critical to ask who paid for it. The answer is clear. Investors got a company without bank debt, but also almost without a core business. That matters because otherwise it is too easy to say "clean balance sheet" and forget that the cleanliness was purchased by selling the key asset.

Even in market terms, this is now a high-friction stock. Market cap is about NIS 29 million, the last price was around 15.9 agorot, and the latest daily turnover was about NIS 63.8 thousand. Short interest data is close to irrelevant, with short float at 0.00% in the latest reading and around 0.15% for much of 2025. That does not mean the market is relaxed. It means the stock is simply too thin for a meaningful short positioning story.

Forecasts And The Road Ahead

Before turning to the forecast itself, four non-obvious findings from the evidence set need to be locked in:

1. The smaller total loss in 2025 does not reflect healing in the surviving business. It mainly reflects a one-off gain from selling the old business.
2. The business tail that remains now depends at the same time on a dominant customer and a dominant supplier, so fragility is already built into the model.
3. The Tomer transaction is not a normal growth acquisition. It is a business-model and control-structure replacement.
4. Tomer brings real scale, but also working-capital intensity, bank debt, and covenant pressure severe enough to push all its bank loans into short-term classification.

This is a forced bridge year, not a breakout year

If 2026 needs a name, it is not a breakout year. It is a forced bridge year. The aftermarket activity may still produce some revenue from existing customers through June 30, 2026, but at the same time the supplier notice means the company may not be able to replenish supply in time. It is therefore hard to see how the remaining activity alone could create a real turning point.

The real trigger is the Tomer deal. And here the analysis has to test both sides, what it fixes and what it adds.

On one side, Tomer brings a level of operating mass that the listed shell today is nowhere near. Based on the audited financials attached to the shareholder-meeting notice, Tomer ended 2025 with NIS 244.9 million of revenue, NIS 47.2 million of gross profit, NIS 12.3 million of operating profit, NIS 20.4 million of EBITDA, and NIS 3.1 million of net profit.

On the other side, Tomer’s balance-sheet numbers matter at least as much. At the end of 2025 it had only NIS 4.341 million of cash, against NIS 66.575 million of bank loans and NIS 24.192 million of equity. More importantly, the filing says explicitly that Tomer was not in compliance with its financial covenants at year-end 2025 and year-end 2024, and that as a result all bank loans were classified as short term.

This is exactly where the writing has to stay two-sided. The Tomer transaction can absolutely solve Cipia’s scale problem, its revenue problem, and even the question of what the company really is. But it does not import a clean engine. It imports a food-import and distribution business with heavy working-capital needs, bank dependence, and built-in FX sensitivity.

Tomer gives, but Tomer also takes

There is another important paradox here. Tomer generated positive operating cash flow of NIS 28.1 million in 2025, but financing cash flow was negative NIS 25.8 million, mainly because of bank-debt repayment. So yes, the operating cash engine works, but a meaningful part of that cash is already spoken for by the funding structure.

For Cipia shareholders, the implication is straightforward. If the deal closes, the listed company will gain a real revenue engine, but the market’s focus will quickly shift to working-capital quality, banking access, and the ability to grow without importing further dilution or financing strain. This is a sharp shift from tech-commercialization risk toward credit, working capital, and covenant risk.

What must happen over the next 2 to 4 quarters

The transaction still requires shareholder approval, TASE approval for listing the issued shares, a tax ruling, the absence of a material adverse change, and third-party approvals. In addition, the company must have at least NIS 8.375 million of cash at closing, and the documents say explicitly that if it is not expected to meet that condition it may need to carry out a public offering.

That means the short-term roadmap splits into two possible tracks:

There is also an FX layer that matters more than it first seems. At Cipia, most cash and much of the revenue were dollar-denominated, while the minimum cash condition for Tomer is in shekels. At Tomer, the direction is almost reversed, sales are in shekels while roughly 80% of purchases are foreign-currency denominated. So even if the deal closes, the story does not leave FX sensitivity behind. It simply changes form.

Risks

The first risk is that the deal does not close

If the Tomer transaction fails, what remains is a company with 5 employees, immaterial inventory, a time-limited aftermarket tail, sharp dependence on Royaltek, and an explicit going-concern warning from the auditors. That is not a theoretical downside case. The company itself flags failure to complete the Tomer transaction and the possible need for external financing as company-specific risks with a high impact rating.

The second risk is that the deal does close, but replaces one problem with another

This sounds paradoxical, but it is real. The transaction could absolutely solve Cipia’s problem of operating scale. But it could also bring shareholders into a more leveraged business, one that is more dependent on working capital, and one that relies on banks that have already forced a short-term classification of all loans. That is an improvement in operating mass, but not automatically an improvement in business quality.

The third risk is operational and immediate

Royaltek is a material supplier, and the company depends on it for development and supply of CIPIA FS-10 units. The March 2026 delay notice turns that dependence from a theoretical risk into an immediate one. As long as the supply chain cannot replenish in time, the company is effectively living off existing inventory that it itself describes as immaterial.

The fourth risk is concentration

In 2025 INTCOMEX accounted for 87% of revenue and another customer for 10%. That is concentration that leaves almost no room for error. Once the company itself says customers are examining alternatives, this is no longer just an abstract "customer loss" risk. It flows directly from the company’s own reduction in activity.

The fifth risk sits in market structure

The tiny trading volumes and low market cap are not background details. They affect the real ability to raise equity, the intensity of dilution if that equity is needed, and the way the market reacts to both good news and bad news. This is a company where weak liquidity turns every capital-markets move into a major issue.

Conclusions

Cipia at the end of 2025 is no longer a technology story waiting for a breakout. It is a company that sold most of its core business, kept a thin shell and a very small aftermarket tail, and is trying to switch into another business before the remaining activity erodes further. What supports the thesis today is a relatively clean balance sheet at the Cipia level and the possibility of importing real operating scale through Tomer. What blocks it is that the bridge there runs through heavy dilution, a long condition set, and financing risk that does not disappear, it merely changes shape.

Current thesis: Cipia is not an automotive-tech recovery story, but a public shell trying to replace its business engine in time.

What changed: In 2024 it still made sense to read the company through the question of whether its driver-monitoring technology could scale. In 2025 the core business was sold, the material IP moved out, and the debate shifted to whether the Tomer bridge closes and on what terms.

Counter-thesis: It is possible to argue that the old report hardly matters anymore, because if Tomer closes, investors get a food business with about NIS 245 million of revenue, about NIS 20 million of EBITDA, and positive operating cash flow. That is a fair argument, but it ignores that the transition is still incomplete, and that the business coming in also brings debt, working-capital intensity, and covenant issues.

What may change the market reading in the short to medium term: shareholder approval, regulatory progress, any signal on whether a public capital raise is needed, and any new data point on the timing of the Tomer close. At the same time, any sign that the aftermarket tail cannot even carry the interim period could weigh heavily.

Why this matters: because the gap between "there is a signed transaction" and "there is a stable business for shareholders" is the whole story here.

Over the next 2 to 4 quarters, what needs to happen for the thesis to strengthen is also fairly clear. The Tomer deal has to close without an overly expensive capital raise and without a worsening in funding terms, and the incoming business has to prove that it brings not just revenue but a sturdier base than the shell Cipia has been left with. What would weaken the thesis is either failure to complete the transaction, or completion at the price of further dilution and financing stress that leaves investors feeling the company changed its story without really solving its quality problem.